Metafora Biosystems

Metafora develops a platform for the discovery, development and distribution of blood tests that detect abnormalities in cellular energetics.

Using RBDs (Receptor Binding Domains), patented reagents that quantify cell nutrient transporters, coupled with powerful algorithms, the platform is able to detect abnormal nutrient consumption that may be the cause of illnesses such as neuro-metabolic diseases, cancer or inflammatory disorders.

Its first product, awarded CE marking in 2017, is a specific, rapid and reliable test to help diagnose De Vivo disease (also known as GLUT1 deficiency syndrome), a seldom diagnosed rare disease. Metafora obtained Forfait Innovation funding for this test in 2018 and will soon kickstart a 30-month clinical trial in over 60 centers across France.

Founded in 2011, Metafora is led by an experienced team and holds six patent families. The company, based in Evry and Paris, has already raised $5M from business angels and has a dozen employees.